Tirzepatide typical research dosing
Across the available literature, Tirzepatide is most commonly administered at 2500–15000 mcg per dose, 1 time(s) per day, via subcutaneous injection. Clinical escalation: 2.5 mg weekly for 4 weeks, then 5, 7.5, 10, 12.5, 15 mg at 4-week intervals as tolerated.
Tirzepatide unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 10 mg Tirzepatide vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 2500 mcg | 8750 mcg | 15000 mcg |
|---|---|---|---|---|
| 1 mL | 10000 mcg/mL | 25.0 units | 87.5 units | 150.0 units |
| 2 mL | 5000 mcg/mL | 50.0 units | 175.0 units | 300.0 units |
| 3 mL | 3333 mcg/mL | 75.0 units | 262.5 units | 450.0 units |
| 5 mL | 2000 mcg/mL | 125.0 units | 437.5 units | 750.0 units |
Tirzepatide cycle length
Most reported Tirzepatide protocols run 20 weeks on, then 0 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
Tirzepatide half-life and timing
Tirzepatide has a half-life of approximately 120 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.